Hexadecylphosphocholine, a New Ether Lipid Analogue Studies on the Antineoplastic Activity in Vitro and in Vivo

Authors

  • C. Unger Department of Internal Medicine, Division of Hematology/Oncology, University of Göttingen, Max-Planck-Institute for Biophysical Chemistry, D-3400 Göttingen, and Asta Pharma ag, D-4800, Bielefeld, West Germany
  • W. Damenz Department of Internal Medicine, Division of Hematology/Oncology, University of Göttingen, Max-Planck-Institute for Biophysical Chemistry, D-3400 Göttingen, and Asta Pharma ag, D-4800, Bielefeld, West Germany
  • E. A. M. Fleer Department of Internal Medicine, Division of Hematology/Oncology, University of Göttingen, Max-Planck-Institute for Biophysical Chemistry, D-3400 Göttingen, and Asta Pharma ag, D-4800, Bielefeld, West Germany
  • D. J. Kim Department of Internal Medicine, Division of Hematology/Oncology, University of Göttingen, Max-Planck-Institute for Biophysical Chemistry, D-3400 Göttingen, and Asta Pharma ag, D-4800, Bielefeld, West Germany
  • A. Breiser Department of Internal Medicine, Division of Hematology/Oncology, University of Göttingen, Max-Planck-Institute for Biophysical Chemistry, D-3400 Göttingen, and Asta Pharma ag, D-4800, Bielefeld, West Germany
  • P. Hilgard Department of Internal Medicine, Division of Hematology/Oncology, University of Göttingen, Max-Planck-Institute for Biophysical Chemistry, D-3400 Göttingen, and Asta Pharma ag, D-4800, Bielefeld, West Germany
  • J. Engel Department of Internal Medicine, Division of Hematology/Oncology, University of Göttingen, Max-Planck-Institute for Biophysical Chemistry, D-3400 Göttingen, and Asta Pharma ag, D-4800, Bielefeld, West Germany
  • G. Nagel Department of Internal Medicine, Division of Hematology/Oncology, University of Göttingen, Max-Planck-Institute for Biophysical Chemistry, D-3400 Göttingen, and Asta Pharma ag, D-4800, Bielefeld, West Germany
  • H. Eibl Department of Internal Medicine, Division of Hematology/Oncology, University of Göttingen, Max-Planck-Institute for Biophysical Chemistry, D-3400 Göttingen, and Asta Pharma ag, D-4800, Bielefeld, West Germany

DOI:

https://doi.org/10.3109/02841868909111249

Keywords:

Hexadecylphosphocholine, ether lipids, antineo- plastic activity, C. UngerC. Unger

Abstract

Hexadecylphosphocholine (He-PC) is a new compound synthesized according to the minimal structural requirements deducted from studies with other ether lipids. In vitro studies on He-PC revealed remarkable antineoplastic activity on HL60, U937, Raji and K562 leukemia cell lines. In addition, He-PC, applied orally, showed a superior effect in the treatment of dimethylbenzanthracene-induced rat mammary carcinomas when compared to intravenously administered cyclophosphamide. After oral application He-PC was well absorbed from the intestine and metabolized in the liver by phospholipases C and D. During a 5-week treatment no hematotoxic effects were detected. In a clinical pilot study on breast cancer patients with widespread skin involvement, topically applied He-PC showed skin tumor regressions without local or systemic side effects.

 

Downloads

Download data is not yet available.

Downloads

Published

1989-01-01

How to Cite

Unger, C., Damenz, W., Fleer, E. A. M., Kim, D. J., Breiser, A., Hilgard, P., … Eibl, H. (1989). Hexadecylphosphocholine, a New Ether Lipid Analogue Studies on the Antineoplastic Activity in Vitro and in Vivo. Acta Oncologica, 28(2), 213–217. https://doi.org/10.3109/02841868909111249

Issue

Vol. 28 No. 2 (1989): Acta Oncologica

Section

Articles